Terms: = Endocrine gland cancer AND APOBEC3B, ARP4, 9582, ENSG00000179750, DJ742C19_2, _phorbolin 3_, PHRBNL, FLJ21201, Q9UH17, bK150C2_2, APOBEC1L, ARCD3 AND Treatment
30350 results:
1. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
2. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma.
Li F; Si W; Xia L; Yin D; Wei T; Tao M; Cui X; Yang J; Hong T; Wei R
Mol Cancer; 2024 May; 23(1):90. PubMed ID: 38711083
[TBL] [Abstract] [Full Text] [Related]
3. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract] [Full Text] [Related]
4. QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC treatment.
Shinde A; Panchal K; Patra P; Singh S; Enakolla S; Paliwal R; Chaurasiya A
AAPS PharmSciTech; 2024 May; 25(5):97. PubMed ID: 38710894
[TBL] [Abstract] [Full Text] [Related]
5. Active surveillance is a feasible and safe strategy in selected patients with papillary thyroid cancer and suspicious cervical lymph nodes detected after thyroidectomy.
Solórzano M; Lustig N; Mosso L; Espinoza M; Santana R; Gonzalez H; Montero PH; Cruz F; Solar A; Domínguez JM
Arch Endocrinol Metab; 2024 May; 68():e230146. PubMed ID: 38709151
[TBL] [Abstract] [Full Text] [Related]
6. The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial.
Li X; Cao J; Wang W; Zhu X; Sun Y; Song L; Zhang W; Han Y
Front Endocrinol (Lausanne); 2024; 15():1310223. PubMed ID: 38706697
[TBL] [Abstract] [Full Text] [Related]
7. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
[TBL] [Abstract] [Full Text] [Related]
8. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract] [Full Text] [Related]
9. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
Nan Y; Wu X; Luo Q; Chang W; Zhao P; Zhang L; Liu Z
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2315348121. PubMed ID: 38701117
[TBL] [Abstract] [Full Text] [Related]
10. Changes in the diagnosis of thyroid tumours in the 5th edition of the WHO classification of endocrine neoplasms.
J D
Cesk Patol; 2024; 60(1):59-63. PubMed ID: 38697828
[TBL] [Abstract] [Full Text] [Related]
11. NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.
Cardenas RP; Zyoud A; McIntyre A; Alberio R; Mongan NP; Allegrucci C
Stem Cell Res Ther; 2024 May; 15(1):128. PubMed ID: 38693576
[TBL] [Abstract] [Full Text] [Related]
12. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
13. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract] [Full Text] [Related]
14. The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
Wan Q; Tan L; Tang X; Wang W; Su Y; Wu Z; Ke M; Chen Z
Front Endocrinol (Lausanne); 2024; 15():1327766. PubMed ID: 38686207
[TBL] [Abstract] [Full Text] [Related]
15. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of the Craniopharyngioma Resection via Expanded Endoscopic Endonasal Transsphenoidal Approach in the treatment of Complex Craniopharyngioma and Its Effect on Pituitary Function and Complications of Patients.
Bu X
Ann Ital Chir; 2024; 95(2):192-199. PubMed ID: 38684506
[TBL] [Abstract] [Full Text] [Related]
17. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract] [Full Text] [Related]
18. Understanding autoimmune pancreatitis: Clinical features, management challenges, and association with malignancies.
Christodoulidis G; Kouliou MN; Koumarelas KE
World J Gastroenterol; 2024 Apr; 30(15):2091-2095. PubMed ID: 38681985
[TBL] [Abstract] [Full Text] [Related]
19. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
20. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract] [Full Text] [Related]
[Next]
